6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Function	NNP	function	function	function	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
Mycotic	NNP	mycotic	mycotic	mycot	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Low	NNP	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Density	NN	density	density	densiti	N	I-AdverseReaction
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Bladder	NNP	bladder	bladder	bladder	N	B-AdverseReaction
Cancer	NNP	cancer	cancer	cancer	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
incidence	NN	incidence	incidence	incid	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
AstraZeneca	NNP	astrazeneca	astrazeneca	astrazeneca	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
236	CD	236	236	236	N	O
-	:	-	-	-	N	O
9933	CD	9933	9933	9933	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
for	IN	for	for	for	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
is	VBZ	is	is	is	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
12	CD	12	12	12	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
4	CD	4	4	4	N	O
studies	NNS	studies	study	studi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
studies	NNS	studies	study	studi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
background	VB	background	background	background	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapy	NN	therapy	therapy	therapi	N	O
or	CC	or	or	or	N	O
as	IN	as	a	as	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
metformin	JJ	metformin	metformin	metformin	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
2338	CD	2338	2338	2338	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
21	CD	21	21	21	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1393	CD	1393	1393	1393	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1145	CD	1145	1145	1145	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1193	CD	1193	1193	1193	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Fifty	NNP	fifty	fifty	fifti	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
;	:	;	;	;	N	O
81%	CD	81%	81%	81%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
14%	CD	14%	14%	14%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
A1c	NNP	a1c	a1c	a1c	N	O
(	(	(	(	(	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
8.3%	CD	8.3%	8.3%	8.3%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
21%	CD	21%	21%	21%	N	O
had	VBD	had	had	had	N	O
established	VBN	established	established	establish	N	O
microvascular	JJ	microvascular	microvascular	microvascular	N	O
complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
92%	CD	92%	92%	92%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
moderately	RB	moderately	moderately	moder	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
eGFR	VBP	egfr	egfr	egfr	N	O
86	CD	86	86	86	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
present	JJ	present	present	present	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
on	IN	on	on	on	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNPS	studies	study	studi	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
1393	CD	1393	1393	1393	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
1145	CD	1145	1145	1145	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
1193	CD	1193	1193	1193	N	O

Female	NN	female	female	femal	N	O

genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infectionsGenital	JJ	infectionsgenital	infectionsgenital	infectionsgenit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
females	NNS	females	female	femal	N	I-AdverseReaction
:	:	:	:	:	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvovaginitis	NN	vulvovaginitis	vulvovaginitis	vulvovagin	Y	B-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvitis	NN	vulvitis	vulvitis	vulviti	Y	B-AdverseReaction
,	,	,	,	,	N	O
genitourinary	JJ	genitourinary	genitourinary	genitourinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulval	JJ	vulval	vulval	vulval	N	B-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vaginitis	NN	vaginitis	vaginitis	vagin	Y	B-AdverseReaction
bacterial	NN	bacterial	bacterial	bacteri	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
for	IN	for	for	for	N	O
females	NNS	females	female	femal	N	O
:	:	:	:	:	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
677	CD	677	677	677	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
581	CD	581	581	581	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
598	CD	598	598	598	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

1.5	CD	1.5	1.5	1.5	N	O
8.4	CD	8.4	8.4	8.4	N	O
6.9	CD	6.9	6.9	6.9	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
6.2	CD	6.2	6.2	6.2	N	O
6.6	CD	6.6	6.6	6.6	N	O
6.3	CD	6.3	6.3	6.3	N	O

Urinary	JJ	urinary	urinary	urinari	N	O
tract	NN	tract	tract	tract	N	O
infectionsUrinary	JJ	infectionsurinary	infectionsurinary	infectionsurinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
reported	VBN	reported	reported	report	N	O
:	:	:	:	:	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
Escherichia	NNP	escherichia	escherichia	escherichia	N	B-AdverseReaction
urinary	JJ	urinary	urinary	urinari	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
genitourinary	JJ	genitourinary	genitourinary	genitourinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
pyelonephritis	NN	pyelonephritis	pyelonephritis	pyelonephr	Y	B-AdverseReaction
,	,	,	,	,	N	O
trigonitis	NN	trigonitis	trigonitis	trigon	Y	B-AdverseReaction
,	,	,	,	,	N	O
urethritis	NN	urethritis	urethritis	urethr	Y	B-AdverseReaction
,	,	,	,	,	N	O
kidney	NN	kidney	kidney	kidney	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
prostatitis	NN	prostatitis	prostatitis	prostat	Y	B-AdverseReaction
.	.	.	.	.	N	O

3.7	CD	3.7	3.7	3.7	N	O
5.7	CD	5.7	5.7	5.7	N	O
4.3	CD	4.3	4.3	4.3	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
3.2	CD	3.2	3.2	3.2	N	O
3.1	CD	3.1	3.1	3.1	N	O
4.2	CD	4.2	4.2	4.2	N	O

Increased	VBN	increased	increased	increas	N	O
urinationIncreased	JJ	urinationincreased	urinationincreased	urinationincreas	N	B-AdverseReaction
urination	NN	urination	urination	urin	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
reported	VBN	reported	reported	report	N	O
:	:	:	:	:	N	O
pollakiuria	NN	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urine	JJ	urine	urine	urin	N	B-AdverseReaction
output	NN	output	output	output	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

1.7	CD	1.7	1.7	1.7	N	O
2.9	CD	2.9	2.9	2.9	N	O
3.8	CD	3.8	3.8	3.8	N	O

Male	JJ	male	male	male	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infectionsGenital	JJ	infectionsgenital	infectionsgenital	infectionsgenit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
males	NNS	males	male	male	N	I-AdverseReaction
:	:	:	:	:	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
candida	NN	candida	candida	candida	N	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
male	NN	male	male	male	N	I-AdverseReaction
,	,	,	,	,	N	O
penile	JJ	penile	penile	penil	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
balanoposthitis	NN	balanoposthitis	balanoposthitis	balanoposth	Y	B-AdverseReaction
,	,	,	,	,	N	O
balanoposthitis	NN	balanoposthitis	balanoposthitis	balanoposth	Y	B-AdverseReaction
infective	NN	infective	infective	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
posthitis	NN	posthitis	posthitis	posthiti	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
for	IN	for	for	for	N	O
males	NNS	males	male	male	N	O
:	:	:	:	:	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
716	CD	716	716	716	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
564	CD	564	564	564	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
595	CD	595	595	595	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

0.3	CD	0.3	0.3	0.3	N	O
2.8	CD	2.8	2.8	2.8	N	O
2.7	CD	2.7	2.7	2.7	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
2.4	CD	2.4	2.4	2.4	N	O
2.8	CD	2.8	2.8	2.8	N	O
2.5	CD	2.5	2.5	2.5	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
2.3	CD	2.3	2.3	2.3	N	O
2.7	CD	2.7	2.7	2.7	N	O
2.3	CD	2.3	2.3	2.3	N	O

Dyslipidemia	NNP	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
1.5	CD	1.5	1.5	1.5	N	O
2.1	CD	2.1	2.1	2.1	N	O
2.5	CD	2.5	2.5	2.5	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
1.5	CD	1.5	1.5	1.5	N	O
2.2	CD	2.2	2.2	2.2	N	O
1.9	CD	1.9	1.9	1.9	N	O

Discomfort	NN	discomfort	discomfort	discomfort	Y	B-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
urination	JJ	urination	urination	urin	N	I-AdverseReaction
0.7	CD	0.7	0.7	0.7	N	O
1.6	CD	1.6	1.6	1.6	N	O
2.1	CD	2.1	2.1	2.1	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
1.4	CD	1.4	1.4	1.4	N	O
2.0	CD	2.0	2.0	2.0	N	O
1.7	CD	1.7	1.7	1.7	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
13	CD	13	13	13	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
for	IN	for	for	for	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
tolerability	NN	tolerability	tolerability	toler	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
larger	JJR	larger	larger	larger	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
pool	NN	pool	pool	pool	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
pool	NN	pool	pool	pool	N	O
combined	VBD	combined	combined	combin	N	O
13	CD	13	13	13	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
3	CD	3	3	3	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
9	CD	9	9	9	N	O
add	SYM	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
background	VB	background	background	background	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapy	NN	therapy	therapy	therapi	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
initial	JJ	initial	initial	initi	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
metformin	NN	metformin	metformin	metformin	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
these	DT	these	these	these	N	O
13	CD	13	13	13	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
2360	CD	2360	2360	2360	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
22	CD	22	22	22	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
59	CD	59	59	59	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Fifty	NNP	fifty	fifty	fifti	N	O
-	:	-	-	-	N	O
eight	CD	eight	eight	eight	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
58%	CD	58%	58%	58%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
;	:	;	;	;	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
9%	CD	9%	9%	9%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.2%	CD	8.2%	8.2%	8.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
30%	CD	30%	30%	30%	N	O
had	VBD	had	had	had	N	O
established	VBN	established	established	establish	N	O
microvascular	JJ	microvascular	microvascular	microvascular	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
88%	CD	88%	88%	88%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
moderately	RB	moderately	moderately	moder	N	O
impaired	VBN	impaired	impaired	impair	N	O
in	IN	in	in	in	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
eGFR	VBP	egfr	egfr	egfr	N	O
82	CD	82	82	82	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Volume	NN	volume	volume	volum	N	O
Depletion	NN	depletion	depletion	deplet	N	O

FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
causes	VBZ	causes	cause	caus	N	O
an	DT	an	an	an	N	O
osmotic	JJ	osmotic	osmotic	osmot	N	B-AdverseReaction
diuresis	NN	diuresis	diuresis	diuresi	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
reductions	NNS	reductions	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
intravascular	JJ	intravascular	intravascular	intravascular	N	I-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
volume	NN	volume	volume	volum	N	B-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
study	NN	study	study	studi	N	O
and	CC	and	and	and	N	O
13	CD	13	13	13	N	O
-	:	-	-	-	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pools	NNS	pools	pool	pool	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
Volume	NN	volume	volume	volum	N	B-AdverseReaction
DepletionVolume	NNP	depletionvolume	depletionvolume	depletionvolum	N	I-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
.	.	.	.	.	N	O

in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNPS	studies	study	studi	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNPS	studies	study	studi	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
13	CD	13	13	13	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

Overall	JJ	overall	overall	overal	N	O

population	NN	population	population	popul	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
1393	CD	1393	1393	1393	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
1145	CD	1145	1145	1145	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
1193	CD	1193	1193	1193	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
2295	CD	2295	2295	2295	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
2360	CD	2360	2360	2360	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O

Patient	NNP	patient	patient	patient	N	O
Subgroup	NNP	subgroup	subgroup	subgroup	N	O
n	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
loop	JJ	loop	loop	loop	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
n	JJ	n	n	n	N	O
551	CD	551	551	551	N	O
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
400	CD	400	400	400	N	O
n	JJ	n	n	n	N	O
313	CD	313	313	313	N	O
(	(	(	(	(	N	O
9.7%	CD	9.7%	9.7%	9.7%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2674	CD	2674	2674	2674	N	O
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2366	CD	2366	2366	2366	N	O
(	(	(	(	(	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
with	IN	with	with	with	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
and	CC	and	and	and	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NNS	m2	m2	m2	N	O
n	JJ	n	n	n	N	O
1072	CD	1072	1072	1072	N	O
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
1071	CD	1071	1071	1071	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
891	CD	891	891	891	N	O
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2684	CD	2684	2684	2684	N	O
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2655	CD	2655	2655	2655	N	O
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
n	JJ	n	n	n	N	O
2761	CD	2761	2761	2761	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2161	CD	2161	2161	2161	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
2043	CD	2043	2043	2043	N	O
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
7116	CD	7116	7116	7116	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
66511	CD	66511	66511	66511	N	O
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O

Impairment	NN	impairment	impairment	impair	N	O
of	IN	of	of	of	N	O
Renal	NNP	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
eGFR	NN	egfr	egfr	egfr	N	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
eGFR	NN	egfr	egfr	egfr	N	O
returned	VBN	returned	returned	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
values	NNS	values	value	valu	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
.	.	.	.	.	N	O

Renal	NNP	renal	renal	renal	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Sustained	VBN	sustained	sustained	sustain	N	O
decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
eGFR	NN	egfr	egfr	egfr	N	O
were	VBD	were	were	were	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
and	CC	and	and	and	N	O
eGFR	RB	egfr	egfr	egfr	N	O
Associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
and	CC	and	and	and	N	O
Moderate	NNP	moderate	moderate	moder	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
Study	NNP	study	study	studi	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O

PlaceboN	NN	placebon	placebon	placebon	N	O
1393	CD	1393	1393	1393	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mgN	NN	mgn	mgn	mgn	N	O
1145	CD	1145	1145	1145	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mgN	NN	mgn	mgn	mgn	N	O
1193	CD	1193	1193	1193	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Mean	NNP	mean	mean	mean	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.853	CD	0.853	0.853	0.853	N	O
0.860	CD	0.860	0.860	0.860	N	O
0.847	CD	0.847	0.847	0.847	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
86.0	CD	86.0	86.0	86.0	N	O
85.3	CD	85.3	85.3	85.3	N	O
86.7	CD	86.7	86.7	86.7	N	O

Week	JJ	week	week	week	N	O
1	CD	1	1	1	N	O
Change	NNP	change	change	chang	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.003	CD	0.003	0.003	0.003	N	O
0.029	CD	0.029	0.029	0.029	N	O
0.041	CD	0.041	0.041	0.041	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
0.4	CD	0.4	0.4	0.4	N	O
-	:	-	-	-	N	O
2.9	CD	2.9	2.9	2.9	N	O
-	:	-	-	-	N	O
4.1	CD	4.1	4.1	4.1	N	O

Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
Change	NNP	change	change	chang	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.005	CD	0.005	0.005	0.005	N	O
-	:	-	-	-	N	O
0.001	CD	0.001	0.001	0.001	N	O
0.001	CD	0.001	0.001	0.001	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.3	CD	0.3	0.3	0.3	N	O

Moderate	NNP	moderate	moderate	moder	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
Study	NNP	study	study	studi	N	O

PlaceboN	NNP	placebon	placebon	placebon	N	O
84	CD	84	84	84	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mgN	NN	mgn	mgn	mgn	N	O
83	CD	83	83	83	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mgN	NN	mgn	mgn	mgn	N	O
85	CD	85	85	85	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Mean	NNP	mean	mean	mean	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
1.46	CD	1.46	1.46	1.46	N	O
1.53	CD	1.53	1.53	1.53	N	O
1.52	CD	1.52	1.52	1.52	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
45.6	CD	45.6	45.6	45.6	N	O
44.2	CD	44.2	44.2	44.2	N	O
43.9	CD	43.9	43.9	43.9	N	O

Week	JJ	week	week	week	N	O
1	CD	1	1	1	N	O
Change	NNP	change	change	chang	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
0.13	CD	0.13	0.13	0.13	N	O
0.18	CD	0.18	0.18	0.18	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
0.5	CD	0.5	0.5	0.5	N	O
-	:	-	-	-	N	O
3.8	CD	3.8	3.8	3.8	N	O
-	:	-	-	-	N	O
5.5	CD	5.5	5.5	5.5	N	O

Week	JJ	week	week	week	N	O
24	CD	24	24	24	N	O
Change	NNP	change	change	chang	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.02	CD	0.02	0.02	0.02	N	O
0.08	CD	0.08	0.08	0.08	N	O
0.16	CD	0.16	0.16	0.16	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
0.03	CD	0.03	0.03	0.03	N	O
-	:	-	-	-	N	O
4.0	CD	4.0	4.0	4.0	N	O
-	:	-	-	-	N	O
7.4	CD	7.4	7.4	7.4	N	O

Week	JJ	week	week	week	N	O
52	CD	52	52	52	N	O
Change	NNP	change	change	chang	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.10	CD	0.10	0.10	0.10	N	O
0.06	CD	0.06	0.06	0.06	N	O
0.15	CD	0.15	0.15	0.15	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.6	CD	2.6	2.6	2.6	N	O
-	:	-	-	-	N	O
4.2	CD	4.2	4.2	4.2	N	O
-	:	-	-	-	N	O
7.3	CD	7.3	7.3	7.3	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
One	NNP	one	one	one	N	O
Renal	NNP	renal	renal	renal	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Related	JJ	related	related	relat	N	I-AdverseReaction
Adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
Reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
6	CD	6	6	6	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
104	CD	104	104	104	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
104	CD	104	104	104	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Characteristic	NNP	characteristic	characteristic	characterist	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

Overall	JJ	overall	overall	overal	N	O

populationPatients	NNS	populationpatients	populationpatients	populationpati	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
n	CC	n	n	n	N	O
78513	CD	78513	78513	78513	N	O
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
76714	CD	76714	76714	76714	N	O
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
85916	CD	85916	85916	85916	N	O
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
195682	CD	195682	195682	195682	N	O
(	(	(	(	(	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
2026136	CD	2026136	2026136	2026136	N	O
(	(	(	(	(	N	O
6.7%	CD	6.7%	6.7%	6.7%	N	O
)	)	)	)	)	N	O

65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
Patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
n	NN	n	n	n	N	O
1904	CD	1904	1904	1904	N	O
(	(	(	(	(	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
1625	CD	1625	1625	1625	N	O
(	(	(	(	(	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
)	)	)	)	)	N	O
n	NN	n	n	n	N	O
1596	CD	1596	1596	1596	N	O
(	(	(	(	(	N	O
3.8%	CD	3.8%	3.8%	3.8%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
65552	CD	65552	65552	65552	N	O
(	(	(	(	(	N	O
7.9%	CD	7.9%	7.9%	7.9%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
62087	CD	62087	62087	62087	N	O
(	(	(	(	(	N	O
14.0%	CD	14.0%	14.0%	14.0%	N	O
)	)	)	)	)	N	O

eGFR	RB	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
and	CC	and	and	and	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2Patients	NNS	m2patients	m2patients	m2patient	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
n	CC	n	n	n	N	O
775	CD	775	775	775	N	O
(	(	(	(	(	N	O
6.5%	CD	6.5%	6.5%	6.5%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
887	CD	887	887	887	N	O
(	(	(	(	(	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
75	CD	75	75	75	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
12.0%	CD	12.0%	12.0%	12.0%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
24940	CD	24940	24940	24940	N	O
(	(	(	(	(	N	O
16.1%	CD	16.1%	16.1%	16.1%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
25171	CD	25171	25171	25171	N	O
(	(	(	(	(	N	O
28.3%	CD	28.3%	28.3%	28.3%	N	O
)	)	)	)	)	N	O

65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
and	CC	and	and	and	N	O
eGFR	VB	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
and	CC	and	and	and	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2Patients	NNS	m2patients	m2patients	m2patient	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
n	CC	n	n	n	N	O
412	CD	412	412	412	N	O
(	(	(	(	(	N	O
4.9%	CD	4.9%	4.9%	4.9%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
433	CD	433	433	433	N	O
(	(	(	(	(	N	O
7.0%	CD	7.0%	7.0%	7.0%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
354	CD	354	354	354	N	O
(	(	(	(	(	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
14127	CD	14127	14127	14127	N	O
(	(	(	(	(	N	O
19.1%	CD	19.1%	19.1%	19.1%	N	O
)	)	)	)	)	N	O
n	RB	n	n	n	N	O
13447	CD	13447	13447	13447	N	O
(	(	(	(	(	N	O
35.1%	CD	35.1%	35.1%	35.1%	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
study	NN	study	study	studi	N	O
13	CD	13	13	13	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
for	IN	for	for	for	N	O
treatment	NN	treatment	treatment	treatment	N	O
durations	NNS	durations	duration	durat	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
104	CD	104	104	104	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Eight	CD	eight	eight	eight	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
13	CD	13	13	13	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
were	VBD	were	were	were	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
baseline	JJ	baseline	baseline	baselin	N	O
eGFR	NN	egfr	egfr	egfr	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
45	CD	45	45	45	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	JJ	m	m	m	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Eleven	NNP	eleven	eleven	eleven	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
13	CD	13	13	13	N	O
fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
pattern	NN	pattern	pattern	pattern	N	O
with	IN	with	with	with	N	O
respect	NN	respect	respect	respect	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
anatomic	JJ	anatomic	anatomic	anatom	N	O
site	NN	site	site	site	N	O
of	IN	of	of	of	N	O
fracture	NN	fracture	fracture	fractur	Y	B-AdverseReaction
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

The	DT	the	the	the	N	O

frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
by	IN	by	by	by	N	O
study	NN	study	study	studi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
is	VBZ	is	is	is	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
when	WRB	when	when	when	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
was	VBD	was	wa	wa	N	O
added	VBN	added	added	ad	N	O
to	TO	to	to	to	N	O
sulfonylurea	VB	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	VB	insulin	insulin	insulin	Y	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
MajorMajor	NNP	majormajor	majormajor	majormajor	N	B-Severity
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
episodes	NNS	episodes	episode	episod	N	O
requiring	VBG	requiring	requiring	requir	N	O
external	JJ	external	external	extern	N	O
(	(	(	(	(	N	O
third	JJ	third	third	third	N	O
party	NN	party	party	parti	N	O
)	)	)	)	)	N	O
assistance	NN	assistance	assistance	assist	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
severe	JJ	severe	severe	sever	N	B-Severity
impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
consciousness	NN	consciousness	consciousness	conscious	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
capillary	JJ	capillary	capillary	capillari	N	B-AdverseReaction
or	CC	or	or	or	N	O
plasma	JJ	plasma	plasma	plasma	N	B-AdverseReaction
glucose	JJ	glucose	glucose	glucos	Y	I-AdverseReaction
value	NN	value	value	valu	N	I-AdverseReaction
54	CD	54	54	54	N	I-AdverseReaction
mg	NN	mg	mg	mg	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
and	CC	and	and	and	N	O
prompt	JJ	prompt	prompt	prompt	N	O
recovery	NN	recovery	recovery	recoveri	N	O
after	IN	after	after	after	N	O
glucose	NN	glucose	glucose	glucos	Y	O
or	CC	or	or	or	N	O
glucagon	NN	glucagon	glucagon	glucagon	Y	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

and	CC	and	and	and	N	O
MinorMinor	NNP	minorminor	minorminor	minorminor	N	B-Severity
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
either	CC	either	either	either	N	O
a	DT	a	a	a	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
episode	NN	episode	episode	episod	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
capillary	JJ	capillary	capillary	capillari	N	B-AdverseReaction
or	CC	or	or	or	N	O
plasma	JJ	plasma	plasma	plasma	N	B-AdverseReaction
glucose	JJ	glucose	glucose	glucos	Y	I-AdverseReaction
measurement	NN	measurement	measurement	measur	N	I-AdverseReaction
63	CD	63	63	63	N	I-AdverseReaction
mg	NN	mg	mg	mg	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
need	NN	need	need	need	N	O
for	IN	for	for	for	N	O
external	JJ	external	external	extern	N	O
assistance	NN	assistance	assistance	assist	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
capillary	NN	capillary	capillary	capillari	N	B-AdverseReaction
or	CC	or	or	or	N	O
plasma	NN	plasma	plasma	plasma	N	B-AdverseReaction
glucose	JJ	glucose	glucose	glucos	Y	I-AdverseReaction
measurement	NN	measurement	measurement	measur	N	I-AdverseReaction
63	CD	63	63	63	N	I-AdverseReaction
mg	NN	mg	mg	mg	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
that	WDT	that	that	that	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
qualify	VB	qualify	qualify	qualifi	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
major	JJ	major	major	major	N	O
episode	NN	episode	episode	episod	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
Active	NNP	active	active	activ	N	O
Control	NNP	control	control	control	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

Monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O

(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
75	CD	75	75	75	N	O
N	NNP	n	n	n	N	O
64	CD	64	64	64	N	O
N	NNP	n	n	n	N	O
70	CD	70	70	70	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
137	CD	137	137	137	N	O
N	NNP	n	n	n	N	O
137	CD	137	137	137	N	O
N	NNP	n	n	n	N	O
135	CD	135	135	135	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.5	CD	1.5	1.5	1.5	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O

Active	JJ	active	active	activ	N	O
Control	NNP	control	control	control	N	O
Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
versus	NN	versus	versus	versu	N	O
Glipizide	NNP	glipizide	glipizide	glipizid	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
408	CD	408	408	408	N	O
-	:	-	-	-	N	O
N	CD	n	n	n	N	O
406	CD	406	406	406	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
147	CD	147	147	147	N	O
(	(	(	(	(	N	O
36.0	CD	36.0	36.0	36.0	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1.7	CD	1.7	1.7	1.7	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Glimepiride	NNP	glimepiride	glimepiride	glimepirid	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
146	CD	146	146	146	N	O
N	NNP	n	n	n	N	O
145	CD	145	145	145	N	O
N	NNP	n	n	n	N	O
151	CD	151	151	151	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
6.0	CD	6.0	6.0	6.0	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
109	CD	109	109	109	N	O
-	:	-	-	-	N	O
N	CD	n	n	n	N	O
109	CD	109	109	109	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	$	)]	)]	)]	N	O
0	CD	0	0	0	N	O
-	:	-	-	-	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3.7	CD	3.7	3.7	3.7	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
12.8	CD	12.8	12.8	12.8	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
139	CD	139	139	139	N	O
N	NNP	n	n	n	N	O
141	CD	141	141	141	N	O
N	NNP	n	n	n	N	O
140	CD	140	140	140	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
DPP4	NNP	dpp4	dpp4	dpp4	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
226	CD	226	226	226	N	O
-	:	-	-	-	N	O
N	CD	n	n	n	N	O
225	CD	225	225	225	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	$	)]	)]	)]	N	O
0	CD	0	0	0	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1.3	CD	1.3	1.3	1.3	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
other	JJ	other	other	other	N	O
OADsOAD	NNP	oadsoad	oadsoad	oadsoad	N	O
oral	JJ	oral	oral	oral	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
197	CD	197	197	197	N	O
N	NNP	n	n	n	N	O
212	CD	212	212	212	N	O
N	NNP	n	n	n	N	O
196	CD	196	196	196	N	O

Major	JJ	major	major	major	N	O
[	NN	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O

Minor	NNP	minor	minor	minor	N	O
[	NNP	[	[	[	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
67	CD	67	67	67	N	O
(	(	(	(	(	N	O
34.0	CD	34.0	34.0	34.0	N	O
)	)	)	)	)	N	O
92	CD	92	92	92	N	O
(	(	(	(	(	N	O
43.4	CD	43.4	43.4	43.4	N	O
)	)	)	)	)	N	O
79	CD	79	79	79	N	O
(	(	(	(	(	N	O
40.3	CD	40.3	40.3	40.3	N	O
)	)	)	)	)	N	O

Genital	NNP	genital	genital	genit	N	O
Mycotic	NNP	mycotic	mycotic	mycot	N	O
Infections	NNP	infections	infection	infect	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
5.7%	CD	5.7%	5.7%	5.7%	N	O
on	IN	on	on	on	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
on	IN	on	on	on	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
study	NN	study	study	studi	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pool	NN	pool	pool	pool	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
from	IN	from	from	from	N	O
study	NN	study	study	studi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
females	NNS	females	female	femal	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
males	NNS	males	male	male	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
were	VBD	were	were	were	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
in	IN	in	in	in	N	O
females	NNS	females	female	femal	N	O
and	CC	and	and	and	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
in	IN	in	in	in	N	O
males	NNS	males	male	male	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
than	IN	than	than	than	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
(	(	(	(	(	N	O
10.0%	CD	10.0%	10.0%	10.0%	N	O
,	,	,	,	,	N	O
23.1%	CD	23.1%	23.1%	23.1%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
25.0%	CD	25.0%	25.0%	25.0%	N	O
versus	NN	versus	versus	versu	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
,	,	,	,	,	N	O
5.9%	CD	5.9%	5.9%	5.9%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
program	NN	program	program	program	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
;	:	;	;	;	N	O
treat	NN	treat	treat	treat	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

Increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
Hematocrit	NNP	hematocrit	hematocrit	hematocrit	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
13	CD	13	13	13	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
mean	JJ	mean	mean	mean	N	I-AdverseReaction
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	I-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
starting	VBG	starting	starting	start	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
continuing	VBG	continuing	continuing	continu	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
Week	VB	week	week	week	N	O
16	CD	16	16	16	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
maximum	JJ	maximum	maximum	maximum	N	O
mean	JJ	mean	mean	mean	N	O
difference	NN	difference	difference	differ	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
-	:	-	-	-	N	O
0.33%	CD	0.33%	0.33%	0.33%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
2.30%	CD	2.30%	2.30%	2.30%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

By	IN	by	by	by	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	B-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
55%	CD	55%	55%	55%	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	SYM	mg	mg	mg	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Inorganic	NNP	inorganic	inorganic	inorgan	N	O
Phosphorus	NNP	phosphorus	phosphorus	phosphoru	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
13	CD	13	13	13	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
mean	JJ	mean	mean	mean	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
in	IN	in	in	in	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	O
of	IN	of	of	of	N	O
0.13	CD	0.13	0.13	0.13	N	O
versus	NN	versus	versus	versu	N	O
-	:	-	-	-	N	O
0.04	CD	0.04	0.04	0.04	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Higher	JJR	higher	higher	higher	N	O
proportions	NNS	proportions	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
marked	JJ	marked	marked	mark	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
of	IN	of	of	of	N	O
hyperphosphatemia	NN	hyperphosphatemia	hyperphosphatemia	hyperphosphatemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
for	IN	for	for	for	N	O
age	NN	age	age	age	N	O
17	CD	17	17	17	N	O
-	:	-	-	-	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
5.1	CD	5.1	5.1	5.1	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
for	IN	for	for	for	N	O
age	NN	age	age	age	N	O
66	CD	66	66	66	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
on	IN	on	on	on	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
versus	NN	versus	versus	versu	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Increase	NNP	increase	increase	increas	N	O
in	IN	in	in	in	N	O
Low	NNP	low	low	low	N	O
-	:	-	-	-	N	O
Density	NN	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
13	CD	13	13	13	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
mean	JJ	mean	mean	mean	N	I-AdverseReaction
lipid	JJ	lipid	lipid	lipid	N	I-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Mean	JJ	mean	mean	mean	N	O
percent	NN	percent	percent	percent	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
versus	NN	versus	versus	versu	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
for	IN	for	for	for	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
and	CC	and	and	and	N	O
-	:	-	-	-	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
versus	NN	versus	versus	versu	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
for	IN	for	for	for	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
:	:	:	:	:	N	O
Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
and	CC	and	and	and	N	O
correct	VB	correct	correct	correct	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
or	CC	or	or	or	N	O
low	JJ	low	low	low	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
insulin	JJ	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
if	IN	if	if	if	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Bladder	NN	bladder	bladder	bladder	N	B-AdverseReaction
Cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
:	:	:	:	:	N	O
An	DT	an	an	an	N	O
imbalance	NN	imbalance	imbalance	imbal	N	O
in	IN	in	in	in	N	O
bladder	NN	bladder	bladder	bladder	N	B-AdverseReaction
cancers	NNS	cancers	cancer	cancer	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
bladder	NN	bladder	bladder	bladder	N	O
cancer	NN	cancer	cancer	cancer	Y	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
bladder	NN	bladder	bladder	bladder	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypotension	NN	hypotension	hypotension	hypotens	Y	O

FARXIGA	NN	farxiga	farxiga	farxiga	N	O

causes	NNS	causes	cause	caus	N	O
intravascular	JJ	intravascular	intravascular	intravascular	N	B-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
contraction	NN	contraction	contraction	contract	N	I-AdverseReaction
.	.	.	.	.	N	O

Symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	CD	]	]	]	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
(	(	(	(	(	N	O
eGFR	RB	egfr	egfr	egfr	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
loop	JJ	loop	loop	loop	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
,	,	,	,	,	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
and	CC	and	and	and	N	O
corrected	VBN	corrected	corrected	correct	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Impairment	NNP	impairment	impairment	impair	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O

FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
increases	VBZ	increases	increase	increas	N	B-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
eGFR	NN	egfr	egfr	egfr	N	I-AdverseReaction
.	.	.	.	.	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
renal	JJ	renal	renal	renal	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
and	CC	and	and	and	N	O
monitored	VBD	monitored	monitored	monitor	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O

Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
can	MD	can	can	can	N	B-Factor
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
when	WRB	when	when	when	N	O
combined	VBN	combined	combined	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
insulin	JJ	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
these	DT	these	these	these	N	O
agents	NNS	agents	agent	agent	N	O
are	VBP	are	are	are	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Genital	NNP	genital	genital	genit	N	O
Mycotic	NNP	mycotic	mycotic	mycot	N	O
Infections	NNP	infections	infection	infect	N	O

FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
appropriately	RB	appropriately	appropriately	appropri	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Low	NNP	low	low	low	N	O
-	:	-	-	-	N	O
Density	NN	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
)	)	)	)	)	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
occur	VBP	occur	occur	occur	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
treat	VB	treat	treat	treat	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Bladder	NNP	bladder	bladder	bladder	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

Across	IN	across	across	across	N	O
22	CD	22	22	22	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
newly	RB	newly	newly	newli	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
bladder	NN	bladder	bladder	bladder	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10	CD	10	10	10	N	O
6045	CD	6045	6045	6045	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.17%	CD	0.17%	0.17%	0.17%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
3512	CD	3512	3512	3512	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.03%	CD	0.03%	0.03%	0.03%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
comparator	NN	comparator	comparator	compar	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
excluding	VBG	excluding	excluding	exclud	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
was	VBD	was	wa	wa	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
bladder	NN	bladder	bladder	bladder	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
4	CD	4	4	4	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
comparator	NN	comparator	comparator	compar	N	O
.	.	.	.	.	N	O

Bladder	NNP	bladder	bladder	bladder	N	O
cancer	NN	cancer	cancer	cancer	Y	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
and	CC	and	and	and	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
indicator	NN	indicator	indicator	indic	N	O
of	IN	of	of	of	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
tumors	NNS	tumors	tumor	tumor	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
balanced	VBN	balanced	balanced	balanc	N	O
between	IN	between	between	between	N	O
treatment	NN	treatment	treatment	treatment	N	O
arms	NNS	arms	arm	arm	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
too	RB	too	too	too	N	O
few	JJ	few	few	few	N	O
cases	NNS	cases	case	case	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
is	VBZ	is	is	is	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
data	NNS	data	data	data	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
has	VBZ	has	ha	ha	N	O
an	DT	an	an	an	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
bladder	NN	bladder	bladder	bladder	N	O
tumors	NNS	tumors	tumor	tumor	N	O
.	.	.	.	.	N	O

Consequently	RB	consequently	consequently	consequ	N	O
,	,	,	,	,	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
bladder	NN	bladder	bladder	bladder	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
bladder	NN	bladder	bladder	bladder	N	O
cancer	NN	cancer	cancer	cancer	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
glycemic	JJ	glycemic	glycemic	glycem	N	O
control	NN	control	control	control	N	O
versus	IN	versus	versus	versu	N	O
unknown	JJ	unknown	unknown	unknown	N	O
risks	NNS	risks	risk	risk	N	O
for	IN	for	for	for	N	O
cancer	NN	cancer	cancer	cancer	Y	O
recurrence	NN	recurrence	recurrence	recurr	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
FARXIGA	NNP	farxiga	farxiga	farxiga	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

